Table 4.
SVR rates according to different therapeutic regimens, genotypes and presence of cirrhosis.
| Therapeutic regimens | General n/N (%) |
Cirrhotic n/N (%) |
Non-cirrhotic n/N (%) |
p-Value |
|---|---|---|---|---|
| Genotype 1 | 0.8415 | |||
| SOF/DAC | 179/183 (97.8) | 74/76 (97.4) | 105/107 (98.1) | |
| SOF/DAC/RIB | 223/233 (95.7) | 136/143 (95.1) | 87/90 (96.6) | |
| SOF/SIM | 137/155 (88.4) | 51/58 (87.9) | 86/97 (88.6) | |
| SOF/SIM/RIB | 35/35 (100.0) | 24/24 (100.0) | 11/11 (100.0) | |
| Total | 574/606 (94.7) | 285/301 (94.7) | 289/305 (94.7) | |
| Genotype 2 | 0.125 | |||
| SOF/RIB | 55/60 (91.7) | 26/28 (92.9) | 29/32 (90.6) | |
| Genotype 3 | 0.3516 | |||
| PEG/RIB/SOF | 28/31 (90.3) | 20/22 (90.9) | 8/9 (88.8) | |
| SOF/DAC | 87/103 (84.5) | 36/41 (87.8) | 51/62 (82.3) | |
| SOF/DAC/RIB | 192/202 (95.0) | 150/158 (94.9) | 42/44 (95.4) | |
| Total | 307/336 (91.4) | 206/221 (93.2) | 101/115 (87.8) | |
PEG, pegylated interferon; RIB, ribavirin; SOF, sofosbuvir; DAC, daclatasvir; SIM, simeprevir.